ALXN - アレクション・ファ―マシュ―ティカルズ （Alexion Pharmaceuticals Inc.） アレクション・ファ―マシュ―ティカルズALXNのチャート
ALXNの企業情報
| symbol | ALXN |
|---|---|
| 会社名 | Alexion Pharmaceuticals Inc. （アレクション・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 アレクシオン・ファーマシューティカル（Alexion Pharmaceuticals Inc.）はバイオ医薬品会社である。同社は治療薬の開発と商品化に集中する。同社の製品はソリリス（エクリズマブ）、Strensiq（アスファターゼアルファ）およびカヌマ（セベリパーゼアルファ）などを含む。同社の臨床開発プログラムはソリリス（エクリズマブ）、cPMP（ALXN1101）、SBC-103、ALXN1210（IV）およびALXN1210（皮下）などを含む。同社のソリリスは発作性夜間ヘモグロビン尿症（PNH）と溶血性尿毒症症候群（aHUS）患者向けの承認された治療薬である。PNHとaHUSは免疫システムの補完成分の慢性的な制御不能な活性化に起因した。同社のStrensiqは低ホスファターゼ患者向けの治療薬である。同社の製品Kanumaはリソソーム酸リパーゼ欠損症（LAL-D）患者向けの治療薬である。KanumaはヒトLAL酵素の組換え型であり、LAL-D患者の治療用補充療法である。 アレクション・ファ―マシュ―ティカルズはバイオ医薬品の世界大手。主な医薬品に発作性夜間血色素尿症と非定型溶血性尿毒症の治療薬ソリリス「Soliris」を開発。また、遺伝性血液障害に対する医薬品も開発。各種の臨床プログラムや、臨床試験のための酵素補充療法も提供。本社は米国コネチカット州。 Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. |
| 本社所在地 | 121 Seaport Boulevard Boston MA 02210 USA |
| 代表者氏名 | David R. Brennan デヴィッド・R・ブレナン |
| 代表者役職名 | independent Chairman of the Board |
| 電話番号 | +1 475-230-2596 |
| 設立年月日 | 33604 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1996年 |
| 従業員数 | 2525人 |
| url | www.alexion.com |
| nasdaq_url | https://www.nasdaq.com/symbol/alxn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 1451.8 |
| 終値（lastsale） | 129.46 |
| 時価総額（marketcap） | 28851345300.08 |
| 時価総額 | 時価総額（百万ドル） 29100.95 |
| 売上高 | 売上高（百万ドル） 3745 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 31128.75 |
| 当期純利益 | 当期純利益（百万ドル） -15.80000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Alexion Pharmaceuticals Inc. revenues increased 11% to $1.98B. Net loss before extraordinary items totaled $169.9M vs. income of $335M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Selling/General/Admin. Expense increase of 31% to $278.6M (expense). |
ALXNのテクニカル分析
ALXNのニュース
ICER finds Alexion''s Soliris lacks cost-effectiveness for myasthenia gravis 2021/07/22 14:09:02 Seeking Alpha
Acquisition of Alexion completed 2021/07/21 18:43:02 CompanyNewsHQ
21 July 2021 13:45 BST NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN View post on CompanyNewsHQ : Acquisition of Alexion completed
Samson Rock Capital LLP Buys Proofpoint Inc, Alexion Pharmaceuticals Inc, Nuance Communications ... 2021/07/20 20:38:09 GuruFocus
Related Stocks: ALXN , WORK , XLNX , PFPT , NUAN , WLTW , PPD , KSU , QTS , VAR , RP , GLUU , WIFI , CLGX , PS ,
Alexion''s Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms 2021/07/20 18:37:04 Benzinga
Ultomiris, the successor to Alexion Pharmaceuticals Inc''s (NASDAQ: ALXN ) paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster year. The drug posted $701 million in sales during 1H of 2021, Alexion said in a recent securities filing , a whopping 48% Full story available on Benzinga.com